Send to

Choose Destination
J Med Chem. 2007 Feb 22;50(4):607-10. Epub 2007 Jan 23.

Identification of a nonpeptidic and conformationally restricted bradykinin B1 receptor antagonist with anti-inflammatory activity.

Author information

Chemistry Research and Development, Neuroscience, HTS/Molecular Pharmacology, Molecular Structure and Design, and Inflammation, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, USA.


We report the discovery of chroman 28, a potent and selective antagonist of human, nonhuman primate, rat, and rabbit bradykinin B1 receptors (0.4-17 nM). At 90 mg/kg s.c., 28 decreased plasma extravasation in two rodent models of inflammation. A novel method to calculate entropy is introduced and ascribed approximately 30% of the gained affinity between "flexible" 4 (Ki = 132 nM) and "rigid" 28 (Ki = 0.77 nM) to decreased conformational entropy.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center